Venrock Adviser, LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Venrock Adviser, LLC disclosed 27 US equity positions worth $2.0bn in its Q4 2025 13F filing. The largest position was APGE at 31.7% of the reported book, followed by ORKA and VRDN. Against the Q3 2025 filing, it opened 1 new position, added to 7 and reduced 4 among the top 27 holdings.
What did Venrock Adviser, LLC own in Q4 2025? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 31.7% | $641.1m | 8,493,321 | 0% | held |
| 2 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 6.2% | $125.7m | 4,148,428 | 0% | held |
| 3 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 6.0% | $120.8m | 3,882,709 | 0% | held |
| 4 | SYRE SPYRE THERAPEUTICS INC | 6.0% | $120.7m | 3,685,448 | 37% | added | |
| 5 | 4XC1 KALVISTA PHARMACEUTICALS INC | 5.4% | $108.7m | 6,728,985 | 0% | held | |
| 6 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 4.4% | $88.8m | 7,315,547 | -44% | reduced |
| 7 | SVRA SAVARA INC | Healthcare | 4.1% | $82.9m | 13,740,375 | 8% | added |
| 8 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.5% | $71.0m | 2,000,000 | -50% | reduced |
| 9 | ERAS ERASCA INC | Healthcare | 3.3% | $66.4m | 17,857,083 | 0% | held |
| 10 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 3.3% | $66.3m | 15,561,500 | 0% | held |
| 11 | MAZE MAZE THERAPEUTICS INC | 3.2% | $64.2m | 1,548,569 | 26% | added | |
| 12 | JBIO JADE BIOSCIENCES INC | 2.5% | $49.7m | 3,220,364 | 0% | held | |
| 13 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 2.5% | $49.7m | 3,226,331 | 0% | held |
| 14 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.3% | $46.4m | 5,676,230 | -14% | reduced |
| 15 | ENGENE HOLDINGS INC | 2.1% | $43.1m | 4,771,414 | -5% | reduced | |
| 16 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.1% | $42.5m | 2,173,913 | 0% | held |
| 17 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.0% | $41.2m | 1,000,000 | 4% | added |
| 18 | UPB UPSTREAM BIO INC | 1.6% | $31.7m | 1,169,298 | 0% | held | |
| 19 | HELP CYBIN INC | 1.6% | $31.4m | 3,840,250 | – | new | |
| 20 | ZURA ZURA BIO LTD | Healthcare | 1.4% | $28.0m | 5,345,115 | 15% | added |
| 21 | VOR VOR BIOPHARMA INC | 1.3% | $25.4m | 1,943,766 | 289% | added | |
| 22 | CBIO CRESCENT BIOPHARMA INC. | 1.2% | $25.3m | 2,133,576 | 54% | added | |
| 23 | SEPN SEPTERNA INC | 0.8% | $17.0m | 610,808 | 0% | held | |
| 24 | SRZN SURROZEN INC | 0.7% | $14.3m | 632,931 | 0% | held | |
| 25 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.7% | $14.3m | 1,379,965 | 0% | held |
| 26 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.3% | $6.9m | 1,609,569 | 0% | held | |
| 27 | CASIF CASI PHARMACEUTICALS INC | 0.0% | $839.2k | 987,259 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.